Abstract:Pediatric asthma is a chronic pulmonary inflammatory disease featuring hypersecretion of mucus and inflammation in the airway, resulting in dysfunction of the airway smooth muscle. Previous evidence demonstrated that latrophilins, a novel family of receptors, present a beneficial effect on airway smooth muscle cells. In the present study, the therapeutic effects of recombinant human latrophilin 3 (rhLPHN3) antibody (Ab) in patients with pediatric asthma were investigated, and the molecular mechanism underlying the function of LPHN3 in the treatment of asthma in clinical practice was examined. A total of 342 pediatric asthma cases were recruited and randomly divided into three groups, receiving treatment with rhLPHN3 Ab (n=134), salbutamol (n=108) or montelukast (n=100) by nasal aerosolization. Each group received the respective clinically tested dose for 16 weeks. Inflammatory factors interleukin (IL)-10, IL-17, IL-4, matrix metallopeptidase-9 (MMP-9), interferon-γ (IFN-γ) and transforming growth factor-β (TGF-β) levels in peripheral blood mononuclear cells were analyzed prior to and post treatment. The clinical outcomes revealed that pathological alterations were significantly improved following treatment with rhLPHN3 Ab for patients with pediatric asthma when compared with those receiving salbutamol and montelukast. It was also observed that rhLPHN3 Ab downregulated the plasma concentration levels of IL-10, IL-17, IL-4 and MMP-9, and upregulated IFN-γ and TGF-β levels in the three groups. In addition, clinical data demonstrated that rhLPHN3 Ab significantly promoted E-selectin and mucin 5AC expression, as well as improved the activation of nuclear factor (NF)-κB p65 DNA binding activity and the phosphorylation levels of protein kinase A. Furthermore, rhLPHN3 Ab markedly improved adhesion and proliferation of airway smooth muscle cells, which led to promotion of the contraction of these cells. In conclusion, these clinical data suggest that rhLPHN3 Ab serves an important role in the inhibition of inflammatory mediators through downregulation of NF-κB signaling pathway, which contributes to airway remodeling and bronchodilation in patients with pediatric asthma.

Latrophilin Receptors: Novel Bronchodilator Targets in Asthma

A cellular census of human lungs identifies novel cell states in health and in asthma

A cellular census of healthy lung and asthmatic airway wall identifies novel cell states in health and disease

Pulmonary Microrna Profiles Identify Involvement of Creb1 and Sec14l3 in Bronchial Epithelial Changes in Allergic Asthma

Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models

Small-Airway Function Variables in Spirometry, Fractional Exhaled Nitric Oxide, and Circulating Eosinophils Predicted Airway Hyperresponsiveness in Patients with Mild Asthma.

Oncostatin M Expression Induced by Bacterial Triggers Drives Airway Inflammatory and Mucus Secretion in Severe Asthma.

Pharmacological ablation of the airway smooth muscle layer-Mathematical predictions of functional improvement in asthma

Clinical efficacy of recombinant human latrophilin 3 antibody in the treatment of pediatric asthma

Increased β2-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors

A common polymorphism in the Intelectin-1 gene influences mucus plugging in severe asthma

Altered Epithelial Gene Expression in Peripheral Airways of Severe Asthma

Bidirectional Counterregulation of Human Lung Mast Cell and Airway Smooth Muscle β2 Adrenoceptors

β2-Adrenoceptor signaling in airway epithelial cells promotes eosinophilic inflammation, mucous metaplasia, and airway contractility

Bronchial epithelial transcriptomics and experimental validation reveal asthma severity-related neutrophilc signatures and potential treatments

Airway Fibroblasts Isolated from Mouse Model of Allergic Asthma Display Distinct Cellular and Phenotypic Characteristics As Compared to Normal Fibroblasts

RhoA/Rho-kinases in Asthma: from Pathogenesis to Therapeutic Targets

From gene identifications to therapeutic targets for asthma: Focus on great potentials of TSLP, ORMDL3, and GSDMB

Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma

Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones

Genome-wide Association Analysis in Asthma Subjects Identifies SPATS2L As a Novel Bronchodilator Response Gene.